Proposal models of hapten-carriers complexes generated by B2GPI interaction with dialysis membranes and endothelial injury by dialysis system access to body [21–23, 27] could be discarded because the prevalence of IgA aB2GPI antibodies in CKD patients in predialysis or those undergoing peritoneal dialysis is similar to the prevalence observed in hemodialysis patients. Here, CD79A is linked to chronic kidney disease.